Zydus receives final approval from USFDA for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg

Ahmedabad, India, 15 January, 2026

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Eltrombopag Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg (USRLD: Promacta Tablets, 12.5 mg, 25 mg, 50 mg, and 75 mg).

Eltrombopag tablets are indicated for the treatment of thrombocytopenia (low platelet count) in specific blood disorders. Eltrombopag works by stimulating bone marrow cells to produce more platelets, thereby reducing the risk of bleeding.

Eltrombopag tablets will be produced at the group's formulation manufacturing facility at SEZ, Ahmedabad.

Eltrombopag tablets had annual sales of USD 1262.5 mn in the United States (IQVIA MAT Nov-2025).

The group now has 429 approvals and has so far filed 505* ANDAs since the commencement of the filing process in FY 2003-04.

*(*As on 31-Dec-2025)*

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878